175 related articles for article (PubMed ID: 24753182)
1. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.
Gorlick S; Barkauskas DA; Krailo M; Piperdi S; Sowers R; Gill J; Geller D; Randall RL; Janeway K; Schwartz C; Grier H; Meyers PA; Gorlick R; Bernstein M; Marina N
Pediatr Blood Cancer; 2014 Sep; 61(9):1558-64. PubMed ID: 24753182
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.
Aznab M; Khajevand Ahmady M; Jamshidi K; Madani SH; Khazaei S; Shoushtaryzadeh T; Bagheri A
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3005-3009. PubMed ID: 33112560
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.
Zhou H; Randall RL; Brothman AR; Maxwell T; Coffin CM; Goldsby RE
J Pediatr Hematol Oncol; 2003 Jan; 25(1):27-32. PubMed ID: 12544770
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.
Ebb D; Meyers P; Grier H; Bernstein M; Gorlick R; Lipshultz SE; Krailo M; Devidas M; Barkauskas DA; Siegal GP; Ferguson WS; Letson GD; Marcus K; Goorin A; Beardsley P; Marina N
J Clin Oncol; 2012 Jul; 30(20):2545-51. PubMed ID: 22665540
[TBL] [Abstract][Full Text] [Related]
10. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Boulytcheva IV; Soloviev YN; Kushlinskii NE; Mahson AN
Bull Exp Biol Med; 2010 Dec; 150(2):237-42. PubMed ID: 21240382
[TBL] [Abstract][Full Text] [Related]
11. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer.
Olmez OF; Evrensel T; Cubukcu E; Ugras N; Avci N; Canhoroz M; Deligonul A; Hartavi M; Olmez F; Cubukcu S; Tolunay S; Kurt E; Kanat O; Manavoglu O
Asian Pac J Cancer Prev; 2013; 14(7):4115-9. PubMed ID: 23991962
[TBL] [Abstract][Full Text] [Related]
13. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
[TBL] [Abstract][Full Text] [Related]
14. C-erbB-2 expression and prognostic significance in osteosarcoma.
Yalçin B; Gedikoğlu G; Kutluk T; Varan A; Akyüz C; Büyükpamukçu M
Pediatr Blood Cancer; 2008 Aug; 51(2):222-7. PubMed ID: 18421709
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.
Spraker-Perlman HL; Barkauskas DA; Krailo MD; Meyers PA; Schwartz CL; Doski J; Gorlick R; Janeway KA; Isakoff MS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27444. PubMed ID: 30255612
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Chaiyawat P; Pruksakorn D; Phanphaisarn A; Teeyakasem P; Klangjorhor J; Settakorn J
Mod Pathol; 2018 Feb; 31(2):264-274. PubMed ID: 28984297
[TBL] [Abstract][Full Text] [Related]
17. The extremity localized classic osteosarcomas have better survival than the axial non-classics.
Lin L; Deng S; Zhang F; Liang Y; Huang Z
World J Surg Oncol; 2018 Feb; 16(1):39. PubMed ID: 29471883
[TBL] [Abstract][Full Text] [Related]
18. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
19. High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma.
Hu F; Wang W; Zhou HC; Shang XF
World J Surg Oncol; 2014 Sep; 12():287. PubMed ID: 25224568
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma.
Rakesh Kumar V; Gupta N; Kakkar N; Sharma SC
J Cancer Res Ther; 2006; 2(1):20-3. PubMed ID: 17998668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
